What is the share price of Entero Healthcare Solutions Ltd (ENTERO) today?
The share price of ENTERO as on 11th July 2025 is ₹1271.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Entero Healthcare Solutions Ltd (ENTERO) share?
The past returns of Entero Healthcare Solutions Ltd (ENTERO) share are- Past 1 week: 2.59%
- Past 1 month: 2.70%
- Past 3 months: 9.56%
- Past 6 months: -7.16%
- Past 1 year: 16.46%
- Past 3 years: N/A%
- Past 5 years: 10.61%
What are the peers or stocks similar to Entero Healthcare Solutions Ltd (ENTERO)?
The peers or stocks similar to Entero Healthcare Solutions Ltd (ENTERO) include:What is the market cap of Entero Healthcare Solutions Ltd (ENTERO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Entero Healthcare Solutions Ltd (ENTERO) is ₹5532.16 Cr as of 11th July 2025.What is the 52 week high and low of Entero Healthcare Solutions Ltd (ENTERO) share?
The 52-week high of Entero Healthcare Solutions Ltd (ENTERO) is ₹1584.25 and the 52-week low is ₹1069.85.What is the PE and PB ratio of Entero Healthcare Solutions Ltd (ENTERO) stock?
The P/E (price-to-earnings) ratio of Entero Healthcare Solutions Ltd (ENTERO) is 58.34. The P/B (price-to-book) ratio is 3.37.Which sector does Entero Healthcare Solutions Ltd (ENTERO) belong to?
Entero Healthcare Solutions Ltd (ENTERO) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Entero Healthcare Solutions Ltd (ENTERO) shares?
You can directly buy Entero Healthcare Solutions Ltd (ENTERO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Entero Healthcare Solutions Ltd
ENTERO Share Price
1,271.502.40% (+29.80)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ENTERO Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ENTERO Performance & Key Metrics
ENTERO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 58.34 | 3.37 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.68 | 6.41 | 0.79% |
75%
Analysts have suggested that investors can buy this stock
from 4 analysts
Price Upside
Earnings Growth
Rev. Growth
ENTERO Company Profile
Entero Healthcare Solutions is an India-based technology-driven and integrated healthcare products distribution company.
SUNPHARMA
PE Ratio
36.71
36.71
1Y Return
5.71%
5.71%
Buy Reco %
87.10
87.10
CIPLA
PE Ratio
22.75
22.75
1Y Return
1.39%
1.39%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
58.69
58.69
1Y Return
12.03%
12.03%
Buy Reco %
70.83
70.83
MANKIND
PE Ratio
53.44
53.44
1Y Return
21.78%
21.78%
Buy Reco %
81.25
81.25
DRREDDY
PE Ratio
18.46
18.46
1Y Return
4.87%
4.87%
Buy Reco %
50.00
50.00
ENTERO Sentiment Analysis
ENTERO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ENTERO Stock Summary · June 2025
Entero Healthcare Solutions has achieved remarkable financial milestones, reporting over Rs. 5,000 crores in revenue and a profit after tax exceeding Rs. 100 crores, driven by a 30% year-on-year growth. This success stems from strategic acquisitions and an expanded geographic footprint, although challenges in acquisition timing slightly tempered growth expectations. The company is focused on enhancing operational efficiency, targeting a reduction in working capital days to 60, which is expected to bolster cash flow and support ambitious growth targets of 25% to 30% CAGR. With a commitment to maintaining strong EBITDA margins and leveraging technology for improved distribution, Entero is well-positioned to capitalize on the evolving healthcare market dynamics in India.
ENTERO Stock Growth Drivers
ENTERO Stock Growth Drivers
5Significant Financial Achievements
In FY '25, the company achieved over Rs. 5,000 crores in revenue, surpassing a customer
Strategic Growth Initiatives
The company focused on organic scale-up in underserved markets, expanding its geographic footprint to operate
ENTERO Stock Challenges
ENTERO Stock Challenges
7Underperformance in Growth Targets
The company has faced challenges in meeting its growth targets, with reported growth falling short
Challenges in Revenue Recognition and Margin Profitability
Recent adjustments to revenue recognition have raised concerns about their impact on margin profitability, with
ENTERO Forecast
ENTERO Forecasts
Price
Revenue
Earnings
ENTERO Share Price Forecast
ENTERO Share Price Forecast
2025
Current
₹1,271.50
Baseline
Forecast for Jul 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹1,271.50
Baseline
Forecast for Jul 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ENTERO Company Revenue Forecast
ENTERO Company Revenue Forecast
2025
Current
₹5.14
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹5.14
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ENTERO Stock EPS (Earnings Per Share) Forecast
ENTERO Stock EPS (Earnings Per Share) Forecast
2025
Current
₹21.80
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹21.80
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ENTERO
ENTERO
Income
Balance Sheet
Cash Flow
Annual Normal View
ENTERO Income Statement
ENTERO Income Statement
Annual Normal View
| Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,354.28 | 1,783.66 | 2,526.55 | 3,305.72 | 3,936.72 | 5,135.29 | 5,135.28 | |||||||
Raw Materials | 1,277.54 | 1,686.57 | 2,342.47 | 3,051.26 | 3,627.81 | 4,924.23 | 4,924.22 | |||||||
| Power & Fuel Cost | 2.17 | 3.39 | 4.07 | 4.25 | 5.60 | |||||||||
| Employee Cost | 56.13 | 74.94 | 114.81 | 128.14 | 151.15 | |||||||||
| Selling & Administrative Expenses | 23.60 | 32.53 | 33.75 | 55.19 | 65.24 | |||||||||
| Operating & Other expenses | -33.29 | -39.24 | 2.53 | -2.64 | -39.34 | |||||||||
EBITDA | 28.13 | 25.47 | 28.92 | 69.52 | 126.26 | 211.06 | 211.06 | |||||||
| Depreciation/Amortization | 11.50 | 16.28 | 19.75 | 24.24 | 25.02 | 30.69 | 30.69 | |||||||
| PBIT | 16.63 | 9.19 | 9.17 | 45.28 | 101.24 | 180.37 | 180.37 | |||||||
| Interest & Other Items | 12.77 | 20.04 | 28.98 | 48.97 | 65.68 | 41.62 | 41.62 | |||||||
| PBT | 3.86 | -10.85 | -19.81 | -3.69 | 35.56 | 138.75 | 138.75 | |||||||
| Taxes & Other Items | 2.92 | 4.69 | 10.10 | 7.87 | -3.55 | 43.92 | 43.93 | |||||||
| Net Income | 0.94 | -15.54 | -29.91 | -11.56 | 39.11 | 94.83 | 94.82 | |||||||
| EPS | 93.81 | -1,550.90 | -151.44 | -29.04 | 16.43 | 21.80 | 21.80 | |||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
ENTERO Company Updates
ENTERO Stock Peers
ENTERO Past Performance & Peer Comparison
ENTERO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Entero Healthcare Solutions Ltd | 58.34 | 3.37 | — |
| Sun Pharmaceutical Industries Ltd | 36.71 | 5.53 | 0.96% |
| Cipla Ltd | 22.75 | 3.83 | 1.08% |
| Torrent Pharmaceuticals Ltd | 58.69 | 14.78 | 0.18% |
ENTERO Stock Price Comparison
Compare ENTERO with any stock or ETFCompare ENTERO with any stock or ETF
ENTERO
ENTERO Holdings
ENTERO Shareholdings
ENTERO Promoter Holdings Trend
ENTERO Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ENTERO Institutional Holdings Trend
ENTERO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has decreased by 2.29%
ENTERO Shareholding Pattern
ENTERO Shareholding Pattern
ENTERO Shareholding History
ENTERO Shareholding History
Foreign Institutions
Mutual Funds Invested in ENTERO
Mutual Funds Invested in ENTERO
No mutual funds holding trends are available
Top 5 Mutual Funds holding Entero Healthcare Solutions Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.3495% | Percentage of the fund’s portfolio invested in the stock 0.94% | Change in the portfolio weight of the stock over the last 3 months -0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 54/75 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9448% | Percentage of the fund’s portfolio invested in the stock 0.69% | Change in the portfolio weight of the stock over the last 3 months -0.16% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 78/96 (-20) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4669% | Percentage of the fund’s portfolio invested in the stock 0.89% | Change in the portfolio weight of the stock over the last 3 months -0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 63/69 (-2) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ENTERO stock
smallcases containing ENTERO stock
Looks like this stock is not in any smallcase yet.
ENTERO Events
ENTERO Events
ENTERO Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ENTERO has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ENTERO Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ENTERO has not given any dividends in last 5 years
ENTERO Dividends
ENTERO Dividends
Hmm, looks like data is unavailable here. Please come back after some timeENTERO Stock News & Opinions
ENTERO Stock News & Opinions
Articles & Videos
Corporate
Entero Healthcare Solutions to convene AGM
Entero Healthcare Solutions announced that the 7th Annual General Meeting(AGM) of the company will be held on 18 September 2025.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
Entero Healthcare Solutions consolidated net profit rises 22.51% in the March 2025 quarter
Net profit of Entero Healthcare Solutions rose 22.51% to Rs 25.69 crore in the quarter ended March 2025 as against Rs 20.97 crore during the previous quarter ended March 2024. Sales rose 29.48% to Rs 1339.06 crore in the quarter ended March 2025 as against Rs 1034.18 crore during the previous quarter ended March 2024. For the full year,net profit rose 142.44% to Rs 94.82 crore in the year ended March 2025 as against Rs 39.11 crore during the previous year ended March 2024. Sales rose 29.92% to Rs 5095.78 crore in the year ended March 2025 as against Rs 3922.31 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1339.061034.18 29 5095.783922.31 30 OPM %3.652.79 -3.372.85 - PBDT45.7220.70 121 169.4360.57 180 PBT37.2313.56 175 138.7435.56 290 NP25.6920.97 23 94.8239.11 142 Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Entero Healthcare Solutions Ltd leads losers in 'B' group
Oriental Aromatics Ltd, Ravikumar Distilleries Ltd, Capital India Finance Ltd and RACL Geartech Ltd are among the other losers in the BSE's 'B' group today, 28 May 2025.Entero Healthcare Solutions Ltd tumbled 10.98% to Rs 1304.3 at 14:32 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 20732 shares were traded on the counter so far as against the average daily volumes of 2645 shares in the past one month.Oriental Aromatics Ltd lost 10.94% to Rs 380.85. The stock was the second biggest loser in 'B' group.On the BSE, 45902 shares were traded on the counter so far as against the average daily volumes of 7756 shares in the past one month.Ravikumar Distilleries Ltd crashed 9.95% to Rs 29.7. The stock was the third biggest loser in 'B' group.On the BSE, 28042 shares were traded on the counter so far as against the average daily volumes of 4477 shares in the past one month.Capital India Finance Ltd corrected 9.83% to Rs 34.77. The stock was the fourth biggest loser in 'B' group.On the BSE, 1.99 lakh shares were traded on the counter so far as against the average daily volumes of 42280 shares in the past one month.RACL Geartech Ltd pared 7.96% to Rs 1010.1. The stock was the fifth biggest loser in 'B' group.On the BSE, 5799 shares were traded on the counter so far as against the average daily volumes of 2463 shares in the past one month.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Entero Healthcare Solutions announces board meeting date
Entero Healthcare Solutions will hold a meeting of the Board of Directors of the Company on 27 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Entero Healthcare Solutions director resigns
Entero Healthcare Solutions announced the resignation of Vipul Indravadan Desai, as a representative of Prasid Uno Family Trust, as Non-Executive Non Independent Director from the Directorship of the Company w.e.f 29 May 2025. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Entero Healthcare Solutions approves investment up to Rs 8 cr in subsidiary
The board of Entero Healthcare Solutions at its meeting held on 21 March 2025 has approved making an investment upto Rs 8 crore in the equity shares proposed to be issued by its wholly owned subsidiary viz. Rada Medisolutions, in one or more tranches on rights issue basis. The board also approved the transfer of the company's 100% stake held in its two wholly owned subsidiaries viz., Chethana Pharma Distributors (CPDPL) and CPD Pharma (CPD Pharma), to its another wholly owned subsidiary, being Rada Medisolutions (Rada).Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Board of Entero Healthcare Solutions approves change in CFO
The Board of Entero Healthcare Solutions at its meeting held on 21 March 2025 has accepted the resignation of Chebolu Venkataramana Ram from the position of Chief Financial Officer of the company with effect from 10 April 2025. Further, the Board has approved the appointment of Balakrishnan Natesan Kaushik as Chief Financial Officer of the company with effect from 11 April 2025. Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Entero Healthcare Solutions consolidated net profit rises 275.22% in the December 2024 quarter
Net profit of Entero Healthcare Solutions rose 275.22% to Rs 25.44 crore in the quarter ended December 2024 as against Rs 6.78 crore during the previous quarter ended December 2023. Sales rose 36.91% to Rs 1359.00 crore in the quarter ended December 2024 as against Rs 992.63 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1359.00992.63 37 OPM %3.682.88 - PBDT47.5414.32 232 PBT39.448.32 374 NP25.446.78 275 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Entero Healthcare Solutions to conduct board meeting
Entero Healthcare Solutions will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Entero Healthcare Solutions allots 13,940 equity shares under ESOP
Entero Healthcare Solutions has allotted 13,940 equity shares under ESOP on 16 January 2025. Consequently, the paid up equity share capital has increased to Rs. 43,50,77,070/- (consisting of 4,35,07,707 equity shares of face value of Rs. 10 each).Powered by Capital Market - Live
5 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 30.55%, vs industry avg of 10.1%
Over the last 5 years, market share increased from 0.54% to 1.23%
Over the last 5 years, net income has grown at a yearly rate of 151.63%, vs industry avg of 20.04%